RxDoctor Payments DataLook up a doctor →

Jae Eun Lee

Neurology · Bowling Green, KYNPI 1346622792

Payments from drug & device makers

$17,896in general payments, 2019–2025

Across 1,044 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$2K
  • AbbVie$2K
  • UCB, Inc.$2K
  • Pfizer$917
  • Neurocrine Biosciences, Inc.$836
  • AstraZeneca$835
  • plus $11K from 50 others

What the payments were for

  • Food & beverage$17,45998%
  • Education$4372%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen105$1,675
AbbVie144$1,572
UCB, Inc.64$1,521
Pfizer71$917
Neurocrine Biosciences, Inc.34$836
AstraZeneca26$835
MDD US Operations, LLC19$694
EMD Serono, Inc.50$635
Lilly USA, LLC36$541
Jazz Pharmaceuticals Inc.26$497
Lundbeck LLC27$482
Amgen25$453
Novartis38$447
Teva Pharmaceuticals USA, Inc.26$440
Neurelis, Inc.26$425
Bristol Myers Squibb32$420
Catalyst Pharmaceuticals, Inc.19$395
Biohaven Pharmaceutical Holding Company Ltd.23$361
Eisai Inc.17$340
CSL Behring18$332
Mallinckrodt Hospital Products Inc.12$295
Genentech USA, Inc.14$293
Amneal Pharmaceuticals LLC20$293
Johnson & Johnson(2 entities)14$268
Grifols USA, LLC15$265
SK Life Science, Inc.14$256
Argenx US, Inc.12$236
Vanda Pharmaceuticals Inc.9$228
Otsuka America Pharmaceutical, Inc.12$204
Sumitomo Pharma America, Inc.14$163
Octapharma USA, Inc.4$157
Alnylam Pharmaceuticals Inc.9$142
Acadia Pharmaceuticals Inc7$135
TG Therapeutics, Inc.7$124
Supernus Pharmaceuticals, Inc.6$103
Cycle Pharmaceuticals Inc4$101
Sunovion Pharmaceuticals Inc.7$89
ANI Pharmaceuticals, Inc.5$84
Harmony Biosciences LLC3$69
Axsome Therapeutics, Inc.3$64
Takeda Pharmaceuticals U.S.A., Inc.3$64
Biohaven Pharmaceuticals, Inc.3$63
Collegium Pharmaceutical, Inc.3$43
Sanofi2$41
Tersera Therapeutics LLC2$40
Zogenix Inc.2$40
Merck1$34
Xeris Pharmaceuticals, Inc.2$33
Arbor Pharmaceuticals, Inc.2$27
Ceribell, Inc.1$21
Ipsen Biopharmaceuticals, Inc1$20
Impel Pharmaceuticals Inc.1$20
Genentech, Inc.1$19
Upsher-smith Laboratories LLC1$16
Tanabe Pharma America, Inc.1$14
Avion Pharmaceuticals1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,896 in reported general payments places this provider in the 75th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$72,617
Medicare patients
388
Services billed
992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate63$522,783
OctagamImmun Globg(Igg)/Malt/Iga Ov5025$462,414
HizentraImmun Glob G(Igg)/Pro/Iga 0-5023$328,523
Kesimpta PenOfatumumab15$131,030
PonvoryPonesimod13$126,805
PanzygaImmun Glob G(Igg)-Ifas/Glycine12$123,849
IngrezzaValbenazine Tosylate13$110,083
UbrelvyUbrogepant105$108,245
Avonex Pen (4 Pack)Interferon Beta-1a12$97,074
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$84,221
QuliptaAtogepant73$79,022
Nurtec OdtRimegepant Sulfate53$77,117
Emgality PenGalcanezumab-Gnlm84$62,019
Aimovig AutoinjectorErenumab-Aooe71$57,741
Lamictal XrLamotrigine19$45,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Panzyga, Nurtec Odt$917$663,38190 claims
BiogenVumerity$1,675$522,78363 claims
CSL BehringHizentra, Privigen$332$412,74435 claims
AbbVieUbrelvy, Qulipta$1,572$187,266178 claims
Johnson & JohnsonPonvory$268$126,80513 claims
Neurocrine Biosciences, Inc.Ingrezza$836$110,08313 claims
Sunovion Pharmaceuticals Inc.Aptiom$89$26,08915 claims
Otsuka America Pharmaceutical, Inc.Rexulti$204$19,96312 claims
SK Life Science, Inc.Xcopri$256$18,96718 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$103$10,38717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 210 neurology providers in Kentucky.

Other neurology in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →